News
Note: I have covered SEACOR Marine Holdings Inc. or “SEACOR Marine”(NYSE:SMHI) previously, so investors should view this as an update to my earlier articles...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow Samuel Smith has a diverse background that includes being lead analyst and Vice President at several highly regarded...
News
This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish...
News
By Adila McHich, Cameron Liao, Elizabeth Hui and Paul Wightman At a Glance From natural gas supply and demand dynamics to OPEC+ decisions, heightened...
News
Introduction Amundi S.A. (OTCPK:AMDUF) recently reported its Q4 2023 results, which I will discuss below. I will also compare the company relative to one...
News
The tech bubble is back, or at least signs of a bubble are back. While Cloudflare (NYSE:NET) has given up some of its post-earnings...
News
Bitcoin (BTC-USD) is back above $60k. Roughly seven weeks after spot ETF approvals in the United States, the coin has printed six consecutive monthly...
News
Hospital REIT Medical Properties Trust (NYSE:MPW) last week submitted its earnings sheet for the fourth-quarter which widely missed EPS expectations due to the company’s...
News
Alcon, Inc. (NYSE:ALC) Q4 2023 Earnings Conference Call February 28, 2024 5:30 PM ET Company Participants Daniel Cravens – Vice President and Global Head,...
News
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Patrick Christmas – Chief Legal Officer Ken Mills...
News
Trex Company, Inc. (NYSE:TREX) Q4 2023 Earnings Conference Call February 26, 2024 5:00 AM ET Company Participants Casey Kotary – IR Amy Fernandez –...
News
Materialise (NASDAQ:MTLS) is about to emerge from a period of significant investment, which should see the company’s profit margins move higher over the next...
News
Silence Therapeutics (NASDAQ:SLN) is gearing up to report topline 36-week data from its phase 2 ALPACAR-360 study, which is using its drug zerlasiran [formerly...
